Pharming Group logo

Pharming Group(ENXTAM) PHARM

Market Cap€598.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)-99%
5 Year+5%
1 Year-29%
1 Month-8%
€0.86
+1.80%
+0.02Today
Pharming Group last closing stock price
MetricPriceDate
Last closeEUR 0.862026-10-14
Pharming Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.05%EUR 0.862026-10-07
1 month-8.02%EUR 0.942026-09-14
3 month-25.73%EUR 1.162026-07-16
Year to date-39.83%EUR 1.432025-12-31
1 year-29.48%EUR 1.222025-10-14
3 year-21.06%EUR 1.092023-10-13
5 year+5.08%EUR 0.822021-10-15
Since inception-99.1%EUR 93.801999-06-16

Pharming Group Financials at a Glance

Market Cap

€598.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$366.25M

Net Income (TTM)

$9.41M

EPS (TTM)

€0.01

P/E Ratio

74.12

Dividend

€0.00

Beta (Volatility)

0.07 (Low)

Price

€0.86

Volume

5,676,801

Open

€0.85

Previous Close

€0.86

Daily Range

€0.84 - €0.87

52-Week Range

€0.83 - €1.82

Estimated Earnings Date

Nov 5, 2026

PHARM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pharming Group

Pharming Group N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on developing and marketing protein replacement therapies for rare diseases. The company aims to address critical unmet medical needs through innovative solutions, with a strong emphasis on global markets including the United States and Europe.

Products and Services
  • Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema
  • Development pipeline includes rhC1INH for pre-eclampsia and acute kidney injury
  • Leniolisib, a PI3K delta inhibitor for activated PI3K delta syndrome
Growth Outlook
  • Recent quarterly revenue of €90.2 million shows strong market demand
  • Partnerships with Novartis and Orchard Therapeutics enhance development capabilities
  • Pipeline expansion targets multiple rare diseases, increasing potential market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of €90.2 million reflects significant growth
  • Net income of €1.6 million in Q2 2026 indicates improving profitability
  • Current ratio of 3.01 suggests strong liquidity position
Pharming Group N.V. is positioned to capitalize on the growing demand for specialized therapies in the biopharmaceutical sector. The company's flagship product, Ruconest, has established a solid market presence, while ongoing research and development efforts aim to expand its therapeutic offerings. Recent financial performance indicates a positive trajectory, with increasing revenues and a focus on strategic partnerships to enhance growth potential. The strong liquidity position further supports the company's ability to invest in future innovations and market expansion.
AI Generated • Oct 3, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Fabrice Chouraqui, MBA

Website

www.pharming.com

Headquarters

Leiden, ZH 2333 CR, NL

PHARM Financials

Key Financial Metrics (TTM)

Gross Margin

86.50%

Operating Margin

4.00%

Net Income Margin

2.57%

Return on Equity

3.52%

Return on Capital

5.31%

Return on Assets

2.01%

Earnings Yield

1.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

€598.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

707.78M

Volume

5.68M

Avg. Volume

8.77M

Financials (TTM)

Gross Profit

$316.80M

Operating Income

$14.64M

EBITDA

$35.70M

Operating Cash Flow

$31.23M

Capital Expenditure

-$662.01K

Free Cash Flow

$30.56M

Cash & ST Invst.

$158.25M

Total Debt

$126.73M

Pharming Group Performance Analysis

Pharming Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 195,648,93016.3%
20232023-12-31USD 226,910,05416.0%
20242024-12-31USD 274,755,05221.1%
20252025-12-31USD 333,281,36521.3%
Pharming Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-304.4%
Q42025-12-3110.5%
Q12026-03-31-33.7%
Q22026-06-3026.6%
Pharming Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.02-4.7%
20232023-12-31USD -0.01N/A
20242024-12-31USD -0.0210.1%
20252025-12-31USD 0.00N/A
Pharming Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3061.4%
Q42025-12-31-38.1%
Q12026-03-31-198.6%
Q22026-06-30129.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$90.21M

-3.2%

Gross Profit

$75.67M

-10.2%

Gross Margin

83.88%

N/A

Market Cap

€598.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€1.47M

N/A

Employees

407

N/A

Net Income

$1.64M

-65.1%

EBITDA

$5.00M

-48.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$158.25M

+25.6%

Total Debt

$126.73M

-1.2%

Accounts Receivable

$56.97M

+6.8%

Inventory

$65.41M

+2.7%

Long Term Debt

$117.68M

-0.9%

Short Term Debt

$9.05M

-5.4%

Return on Assets

2.01%

N/A

Return on Invested Capital

3.91%

N/A

Free Cash Flow

-$9.74M

-183.9%

Operating Cash Flow

-$9.66M

-182.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$51.39-4.76%
NVDANvidia
$221.30-3.16%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About PHARM

What is the current price of Pharming Group?

Pharming Group is trading at €0.86 per share.

What is the 52-week range for Pharming Group?

Over the past 52 weeks, Pharming Group has traded between €0.83 and €1.82.

How much debt does Pharming Group have?

As of the most recent reporting period, Pharming Group reported total debt of $110.87M.

How much cash does Pharming Group have on hand?

Pharming Group reported $138.44M in cash and cash equivalents in its most recent financial results.

What is Pharming Group’s dividend yield?

Pharming Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services